Sections

SEARCH

\protect\hyperlink{site-content}{Skip to
content}\protect\hyperlink{site-index}{Skip to site index}

\href{https://www.nytimes3xbfgragh.onion/section/politics}{Politics}

\href{https://myaccount.nytimes3xbfgragh.onion/auth/login?response_type=cookie\&client_id=vi}{}

\href{https://www.nytimes3xbfgragh.onion/section/todayspaper}{Today's
Paper}

\href{/section/politics}{Politics}\textbar{}Trump Pressed for Plasma
Therapy. Officials Worry, Is an Unvetted Vaccine Next?

\url{https://nyti.ms/3hxwfm9}

\begin{itemize}
\item
\item
\item
\item
\item
\item
\end{itemize}

\begin{itemize}
\item
  \href{https://www.nytimes3xbfgragh.onion/2020/09/12/us/politics/biden-trump-poll-wisconsin-minnesota.html?action=click\&pgtype=Article\&state=default\&region=TOP_BANNER\&context=storylines_menu}{New
  York Times Poll}
\item
  \href{https://www.nytimes3xbfgragh.onion/interactive/2020/us/elections/election-states-biden-trump.html?action=click\&pgtype=Article\&state=default\&region=TOP_BANNER\&context=storylines_menu}{Paths
  to 270}
\item
  \href{https://www.nytimes3xbfgragh.onion/interactive/2019/us/elections/2020-presidential-election-calendar.html?action=click\&pgtype=Article\&state=default\&region=TOP_BANNER\&context=storylines_menu}{Voting
  Deadlines}
\item
  \href{https://www.nytimes3xbfgragh.onion/interactive/2020/08/31/us/politics/vote-by-mail-deadlines.html?action=click\&pgtype=Article\&state=default\&region=TOP_BANNER\&context=storylines_menu}{Voting
  by Mail}
\item
  \href{https://www.nytimes3xbfgragh.onion/newsletters/politics?action=click\&pgtype=Article\&state=default\&region=TOP_BANNER\&context=storylines_menu}{Politics
  Newsletter}
\end{itemize}

Advertisement

\protect\hyperlink{after-top}{Continue reading the main story}

Supported by

\protect\hyperlink{after-sponsor}{Continue reading the main story}

\hypertarget{trump-pressed-for-plasma-therapy-officials-worry-is-an-unvetted-vaccine-next}{%
\section{Trump Pressed for Plasma Therapy. Officials Worry, Is an
Unvetted Vaccine
Next?}\label{trump-pressed-for-plasma-therapy-officials-worry-is-an-unvetted-vaccine-next}}

New details of how the president has demanded faster action from health
agencies help explain the intensifying concern that he could demand
pre-Election Day approval of a vaccine.

\includegraphics{https://static01.graylady3jvrrxbe.onion/images/2020/09/13/us/politics/13dc-virus-pressure-print/merlin_176088858_7c40db35-8cc8-4bee-b732-68147ec7cd7c-articleLarge.jpg?quality=75\&auto=webp\&disable=upscale}

\href{https://www.nytimes3xbfgragh.onion/by/sharon-lafraniere}{\includegraphics{https://static01.graylady3jvrrxbe.onion/images/2018/07/12/multimedia/author-sharon-lafraniere/author-sharon-lafraniere-thumbLarge.png}}\href{https://www.nytimes3xbfgragh.onion/by/noah-weiland}{\includegraphics{https://static01.graylady3jvrrxbe.onion/images/2019/07/23/reader-center/author-noah-weiland/author-noah-weiland-thumbLarge.png}}\href{https://www.nytimes3xbfgragh.onion/by/michael-d-shear}{\includegraphics{https://static01.graylady3jvrrxbe.onion/images/2018/06/13/multimedia/author-michael-d-shear/author-michael-d-shear-thumbLarge-v2.png}}

By \href{https://www.nytimes3xbfgragh.onion/by/sharon-lafraniere}{Sharon
LaFraniere},
\href{https://www.nytimes3xbfgragh.onion/by/noah-weiland}{Noah Weiland}
and \href{https://www.nytimes3xbfgragh.onion/by/michael-d-shear}{Michael
D. Shear}

\begin{itemize}
\item
  Sept. 12, 2020Updated 1:58 p.m. ET
\item
  \begin{itemize}
  \item
  \item
  \item
  \item
  \item
  \item
  \end{itemize}
\end{itemize}

WASHINGTON --- It was the third week of August, the Republican National
Convention was days away, and President Trump was impatient.

White House officials were anxious to showcase a step forward in the
battle against the coronavirus: an expansion of the use of blood plasma
from recovered patients to treat new ones. For nearly two weeks,
however, the National Institutes of Health had held up emergency
authorization for the treatment, citing lingering concerns over its
effectiveness.

So on Wednesday, Aug. 19, Mr. Trump called Dr. Francis S. Collins, the
director of the N.I.H., with a blunt message.

``Get it done by Friday,'' he demanded.

It wasn't done by Friday, and on Sunday, regulators at the Food and Drug
Administration still had not finished a last-minute data review intended
to ease N.I.H. doubts.

But on Sunday night, the eve of the convention, the president announced,
with the F.D.A.'s approval, that plasma therapy would be available
\href{https://www.nytimes3xbfgragh.onion/2020/08/23/us/politics/fda-plasma-coronavirus.html}{for
wider use}, and he declared that it could reduce deaths by 35 percent,
vastly overstating what the data had shown about the benefits.

Mr. Trump's call to Dr. Collins was a flash point in a pressure campaign
by the White House to bend the nation's public health agencies to his
desire to show progress in the fight against a pandemic that has
\href{https://www.nytimes3xbfgragh.onion/interactive/2020/us/coronavirus-us-cases.html}{killed
more than 192,000 people in the United States}. And it was just one in a
series of moments that have left scientists and regulators across the
public health bureaucracy increasingly worried that the White House
could exert greater pressure to approve a vaccine before Election Day,
even in the absence of agreement on its effectiveness and safety.

On the night of the plasma announcement, Dr. Collins was told to show up
at the White House, where he was given a coronavirus test and then
shunted to the Roosevelt Room as Mr. Trump and others spoke to
journalists in the briefing room.

There, Dr. Collins and Dr. Peter Marks, one of the top regulators at the
Food and Drug Administration and the person most directly responsible
for maintaining the independence and scientific rigor of the vaccine
approval process, watched helplessly as the president and other top
administration officials oversold plasma's effectiveness, creating a
public relations debacle that reverberated for days.

Dr. Collins left the White House after the announcement. But Dr. Marks,
who had pushed for the plasma approval, was escorted to the Oval Office
to spend a few minutes with Mr. Trump and his top aides, who were
celebrating with cupcakes with white icing. In an interview on Friday,
Dr. Marks said he was ``a little bit in a state of shock'' to find
himself there being thanked by the president for his work on the plasma
approval.

Although he described it as ``a brief interaction that really didn't
have any substance,'' health officials who had heard about the encounter
said they feared it could create the impression that the guardrails
between politics and science were being further eroded at a time when
\href{https://www.kff.org/coronavirus-covid-19/report/kff-health-tracking-poll-september-2020/}{the
public is already concerned} about political pressure in assessing the
safety of vaccines and treatments.

Some of those present were taken aback when Mr. Trump, who
\href{https://twitter.com/realdonaldtrump/status/1297138862108663808?lang=en}{a
day earlier had tweeted about a ``deep state''} at the Food and Drug
Administration blocking quick approvals of treatments and vaccines to
hurt him politically, jokingly asked whether Dr. Stephen M. Hahn, the
F.D.A. commissioner, was doing a good job.

\includegraphics{https://static01.graylady3jvrrxbe.onion/images/2020/09/13/us/politics/12dc-virus-pressure2/merlin_172282614_70f86d17-2cdb-43b8-a77c-3306cbf21a7f-articleLarge.jpg?quality=75\&auto=webp\&disable=upscale}

With Election Day just over seven weeks away, Washington is witnessing
the collision of two worlds: a community of largely anonymous government
scientists and doctors who operate in a culture guided by research, data
sets and peer review, and a president famously
\href{https://www.nytimes3xbfgragh.onion/2020/04/28/climate/trump-coronavirus-climate-science.html}{disdainful
of science}, politically wounded by his failures to contain the
coronavirus and now determined to cast himself as moving as fast as
possible to provide Americans with vaccines and treatments.

Government scientists and
\href{https://www.nytimes3xbfgragh.onion/2020/09/08/health/9-drug-companies-pledge-coronavirus-vaccine.html}{pharmaceutical
companies} have begun taking extraordinary steps to counter any
impression that they could sacrifice public safety to political
expediency,
\href{https://www.usatoday.com/story/opinion/2020/09/10/sound-science-to-meet-covid-challenges-fda-career-officials-column/5756948002/}{pledging
publicly} that they are committed to impartial scientific decisions
about fighting the coronavirus.

Dr. Hahn has
\href{https://www.healthaffairs.org/do/10.1377/hblog20200814.996612/full/}{publicly
committed} to vetting any vaccine approval through an advisory committee
of outside experts. In an attempt to add more rigor to the agency's
decision-making process, he said this week that the Food and Drug
Administration intended to issue new guidance on the standards used to
justify emergency use of a vaccine.

``We will not jeopardize the public's trust in our science-based,
independent review of these or any vaccines,'' Dr. Hahn
\href{https://twitter.com/SteveFDA/status/1304454630131281923?s=20}{said
on Twitter on Friday}. ``There's too much at stake.''

The administration has come under withering criticism for
\href{https://www.nytimes3xbfgragh.onion/2020/04/11/us/politics/coronavirus-trump-response.html}{not
acting aggressively enough} to confront the virus and failing, for
example, to push through bureaucratic red tape in the pandemic's early
stages
\href{https://www.nytimes3xbfgragh.onion/2020/03/28/us/testing-coronavirus-pandemic.html}{to
develop diagnostic tests that would work}. White House officials say the
president is now doing exactly what his opponents have assailed him for
not doing: exerting pressure to develop safe and effective drugs and
vaccines as quickly as possible because people are sick and dying, not
because of the timing of the election.

The rushed plasma approval rollout is far from the only aspect of the
government response to the virus that was shaped by pressure from the
White House. The Centers for Disease Control and Prevention has
repeatedly waffled on how much testing is recommended and for whom, and
according to emails
\href{https://www.politico.com/news/2020/09/11/exclusive-trump-officials-interfered-with-cdc-reports-on-covid-19-412809}{first
reported on Friday by Politico}, political appointees at the Department
of Health and Human Services have tried to revise or delay C.D.C.
reports on the coronavirus they believed were unflattering to the
president. The Food and Drug Administration first gave emergency
authorization for use of hydroxychloroquine to treat Covid-19 after Mr.
Trump promoted it, only to be forced to
\href{https://www.nytimes3xbfgragh.onion/2020/06/15/health/fda-hydroxychloroquine-malaria.html}{reverse
itself}.

But the battle over approval of convalescent plasma is particularly
telling because it involves many of the players who would figure in a
far more momentous decision over whether to authorize an emergency
approval for a vaccine.

Over the summer, the debate over plasma evolved from a purely scientific
discussion about its merits to a kind of political loyalty test, laid
bare in presidential remarks in the days before the announcement.

In a news briefing on Aug. 19, Mr. Trump complained that ``people over
there'' --- an apparent reference to the Food and Drug Administration
--- wanted to limit plasma treatment until after the election. In a
Twitter post three days later, he accused ``deep state'' officials at
the agency of slow-walking approvals of Covid-19 vaccines and treatments
to harm him politically.

Like other approaches to dealing with the virus, convalescent plasma was
a subject of scientific debate and disagreement. The pale yellow liquid
that remains after blood is stripped of its red and white cells, it has
been used
\href{https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781783/}{since the
1890s} to treat infectious diseases, including the flu, SARS and Ebola.

Regulators at the Food and Drug Administration, which approves new
treatments, were willing to evaluate convalescent plasma for emergency
approval on the basis of tens of thousands of case studies from a
federally supported Mayo Clinic program. Dr. Collins and other officials
at the N.I.H. wanted its benefits tested with randomized trials, for
which scientists across the country had struggled to recruit patients.
Although N.I.H. did not have regulatory authority, the administration
wanted agreement among all the health agencies on moving ahead with
expanded use of plasma.

In June, Dr. Marks alerted Dr. Deborah L. Birx, the White House
coronavirus response coordinator, that early data from the Mayo Clinic
program looked promising. Mark Meadows, the White House chief of staff,
quickly began agitating for emergency approval, senior administration
officials said.

Image

Recovered Covid-19 patients preparing to donate convalescent plasma in
Seattle this month.Credit...Lindsey Wasson/Reuters

Throughout the summer, the White House has kept a close eye on the Food
and Drug Administration's progress with therapies and possible vaccines.
The president himself calls Dr. Hahn on his cellphone about once a week,
according to a senior administration official.

Mr. Meadows is also in regular contact with Dr. Hahn, who sometimes
makes unscheduled visits to Mr. Meadows's corner suite in the West Wing.

Dr. John C. Fleming, a top adviser to Mr. Meadows, holds a weekly
meeting with Dr. Hahn, Dr. Marks, Dr. Janet Woodcock, a top F.D.A. drug
official, and Eric D. Hargan, the deputy health secretary. Jared
Kushner, the president's senior adviser and son-in-law, was also closely
involved in tracking progress on vaccines and treatments.

For weeks, F.D.A. regulators, backed by Dr. Hahn, insisted the data from
the plasma research was not strong enough to justify approving wider
use. By Aug. 12, though, they were ready to move ahead, deciding plasma
met the comparatively low bar for emergency authorization in which the
potential benefits outweighed the risks.

N.I.H. officials were still arguing for a clinical trial, but the
scientists arrived at a compromise: The Food and Drug Administration
would analyze the data again with fresh results from the Mayo Clinic
program.

Frustrated by the delay, Mr. Trump pressed his case with Alex M. Azar
II, his health secretary.

Two allies of Mr. Kushner's got involved: Brad Smith, a deputy assistant
to the president, and Adam Boehler, the chief executive of the U.S.
International Development Finance Corporation and a former Trump
administration health official.

They talked to Dr. Hahn and Mr. Azar about data that they said showed
that plasma from the Mayo Clinic program was available to only
three-fourths of the hospitals treating Covid-19 patients, leaving 900
hospitals without access to the therapy. While emergency approval was
held up, they noted, Americans were dying.

Matters came to a head on Aug. 19 after The New York Times
\href{https://www.nytimes3xbfgragh.onion/2020/08/19/us/politics/blood-plasma-covid-19.html}{published
an article} saying the plasma approval was on hold because of the N.I.H.
objections. F.D.A. and White House officials were furious that N.I.H.
officials had publicly aired their objections despite negotiations to
resolve the conflict over data. Mr. Trump called Dr. Collins demanding
that plasma be approved within two days.

Dr. Birx and other top health officials also lashed out at Dr. Collins,
asking him to publicly clarify his position, according to senior
administration officials with knowledge of one tense meeting that week.

At the Food and Drug Administration, officials were expecting to finish
the new analysis for the N.I.H. and to announce emergency approval of
plasma as early as Monday, Aug. 24.

Image

Dr. Stephen M. Hahn, the F.D.A. commissioner, has publicly committed to
vetting any vaccine approval through an advisory committee of outside
experts.Credit...Pool photo by Kevin Dietsch

But on the preceding Thursday, they were told that was too late: The
decision had to be announced on Sunday, the day before the start of the
Republican National Convention, ostensibly because making the
announcement during the gathering would appear to be politically driven.

Another obstacle emerged that weekend: New Mayo Clinic data was missing
key entries and could not be used, foiling the reanalysis.

White House officials said they were told by Mr. Azar and Dr. Hahn that
they were ready to make the announcement on Sunday. The president's
communications team quickly put together an event in the White House
briefing room, with Mr. Trump flanked by Dr. Hahn and Mr. Azar. The
F.D.A. called the approval
``\href{https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment}{another
achievement}'' in the administration's battle against the pandemic.

The rush contributed to serious mistakes. Dr. Hahn misinterpreted agency
data and claimed that plasma reduced the mortality rate of Covid-19
patients by 35 percent ---
\href{https://www.nytimes3xbfgragh.onion/2020/08/24/health/fda-blood-plasma.html}{a
substantial exaggeration} of what the research actually showed.

Immediately after the announcement, however, the mood in the Oval Office
was celebratory. Cupcakes were served. Photographs were taken.

Before him on the Resolute Desk, the president had multiple copies of
that day's Wall Street Journal. He noted with pleasure a prominent
article stating that he had forever changed the Republican Party.

Katie Thomas contributed reporting from Chicago, and Mark Mazzetti from
Washington.

\hypertarget{our-2020-election-guide}{%
\section{Our 2020 Election Guide}\label{our-2020-election-guide}}

Updated ~Sept. 12, 2020

\begin{center}\rule{0.5\linewidth}{\linethickness}\end{center}

\begin{itemize}
\item ~
  \hypertarget{the-latest}{%
  \subsection{The Latest}\label{the-latest}}

  \begin{itemize}
  \item
    President Trump has failed to erase Joseph R. Biden Jr.'s lead
    across a set of key swing states,
    \href{https://www.nytimes3xbfgragh.onion/2020/09/12/us/politics/biden-trump-poll-wisconsin-minnesota.html?action=click\&pgtype=Article\&state=default\&region=BELOW_MAIN_CONTENT\&context=storylines_guide}{according
    to a poll}~conducted by The Times and Siena College.
  \end{itemize}
\item ~
  \hypertarget{paths-to-270}{%
  \subsection{Paths to 270}\label{paths-to-270}}

  \begin{itemize}
  \item
    Joe Biden and Donald Trump need 270 electoral votes to reach the
    White House. Try building
    \href{https://www.nytimes3xbfgragh.onion/interactive/2020/us/elections/election-states-biden-trump.html?action=click\&pgtype=Article\&state=default\&region=BELOW_MAIN_CONTENT\&context=storylines_guide}{your
    own coalition of battleground states}~to see potential outcomes.
  \end{itemize}
\item ~
  \hypertarget{voting-deadlines}{%
  \subsection{Voting Deadlines}\label{voting-deadlines}}

  \begin{itemize}
  \item
    Early voting for the presidential election starts in September~in
    some states. Take a look at
    \href{https://www.nytimes3xbfgragh.onion/interactive/2019/us/elections/2020-presidential-election-calendar.html?action=click\&pgtype=Article\&state=default\&region=BELOW_MAIN_CONTENT\&context=storylines_guide}{key
    dates}\href{https://www.nytimes3xbfgragh.onion/interactive/2019/us/elections/2020-presidential-election-calendar.html?action=click\&pgtype=Article\&state=default\&region=BELOW_MAIN_CONTENT\&context=storylines_guide}{where
    you
    liv}\href{https://www.nytimes3xbfgragh.onion/interactive/2019/us/elections/2020-presidential-election-calendar.html?action=click\&pgtype=Article\&state=default\&region=BELOW_MAIN_CONTENT\&context=storylines_guide}{e}.
    If you're voting by
    mail,~\href{https://www.nytimes3xbfgragh.onion/interactive/2020/08/31/us/politics/vote-by-mail-deadlines.html?action=click\&pgtype=Article\&state=default\&region=BELOW_MAIN_CONTENT\&context=storylines_guide}{it's
    risky to procrastinate}.
  \item
    \href{https://www.nytimes3xbfgragh.onion/interactive/2020/us/elections/joe-biden.html?action=click\&pgtype=Article\&state=default\&region=BELOW_MAIN_CONTENT\&context=storylines_guide}{}

    \hypertarget{joe-biden}{%
    \section{Joe Biden}\label{joe-biden}}

    \hypertarget{democrat}{%
    \subsection{Democrat}\label{democrat}}

    \href{https://www.nytimes3xbfgragh.onion/interactive/2020/us/elections/donald-trump.html?action=click\&pgtype=Article\&state=default\&region=BELOW_MAIN_CONTENT\&context=storylines_guide}{}

    \hypertarget{donald-trump}{%
    \section{Donald Trump}\label{donald-trump}}

    \hypertarget{republican}{%
    \subsection{Republican}\label{republican}}
  \end{itemize}
\item
  \hypertarget{keep-up-with-our-coverage}{%
  \subsection{Keep Up With Our
  Coverage}\label{keep-up-with-our-coverage}}

  \begin{itemize}
  \item
    Get an
    \href{https://www.nytimes3xbfgragh.onion/newsletters/politics?action=click\&pgtype=Article\&state=default\&region=BELOW_MAIN_CONTENT\&context=storylines_guide}{email}~recapping
    the day's news
  \item
    Download our mobile app on
    \href{https://apps.apple.com/us/app/nytimes/id284862083?ls=1\&mat_click_id=5c79ae7455014fd1bd66b5610c05b8f2-20191112-16948\&referrer=mat_click_id\%3D5c79ae7455014fd1bd66b5610c05b8f2-20191112-16948\%26link_click_id\%3D722930677036718082}{iOS}~and
    \href{http://a.localytics.com/android?id=com.nytimes.android\&referrer=utm_source\%3Dother_nyt_mobile_web\%26utm_medium\%3DWeb\%2520page\%26utm_term\%3DGeneral\%2520Mobile\%2520Page\%26utm_campaign\%3DNYT\%2520Mobile\%2520General\%2520Page}{Android}~and
    turn on Breaking News and Politics alerts
  \end{itemize}
\end{itemize}

Advertisement

\protect\hyperlink{after-bottom}{Continue reading the main story}

\hypertarget{site-index}{%
\subsection{Site Index}\label{site-index}}

\hypertarget{site-information-navigation}{%
\subsection{Site Information
Navigation}\label{site-information-navigation}}

\begin{itemize}
\tightlist
\item
  \href{https://help.nytimes3xbfgragh.onion/hc/en-us/articles/115014792127-Copyright-notice}{Â©~2020~The
  New York Times Company}
\end{itemize}

\begin{itemize}
\tightlist
\item
  \href{https://www.nytco.com/}{NYTCo}
\item
  \href{https://help.nytimes3xbfgragh.onion/hc/en-us/articles/115015385887-Contact-Us}{Contact
  Us}
\item
  \href{https://www.nytco.com/careers/}{Work with us}
\item
  \href{https://nytmediakit.com/}{Advertise}
\item
  \href{http://www.tbrandstudio.com/}{T Brand Studio}
\item
  \href{https://www.nytimes3xbfgragh.onion/privacy/cookie-policy\#how-do-i-manage-trackers}{Your
  Ad Choices}
\item
  \href{https://www.nytimes3xbfgragh.onion/privacy}{Privacy}
\item
  \href{https://help.nytimes3xbfgragh.onion/hc/en-us/articles/115014893428-Terms-of-service}{Terms
  of Service}
\item
  \href{https://help.nytimes3xbfgragh.onion/hc/en-us/articles/115014893968-Terms-of-sale}{Terms
  of Sale}
\item
  \href{https://spiderbites.nytimes3xbfgragh.onion}{Site Map}
\item
  \href{https://help.nytimes3xbfgragh.onion/hc/en-us}{Help}
\item
  \href{https://www.nytimes3xbfgragh.onion/subscription?campaignId=37WXW}{Subscriptions}
\end{itemize}
